专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2542256B1 ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS THEREOF AND USES THEREOF 有权转让
公开(公告)号：EP2542256B1
公开(公告)日：2019-05-22
申请号：EP11751204.6
申请日：2011-03-01
申请人： MacroGenics, Inc.
发明人： LOO, Deryk, T. , HUANG, Ling , CHEN, Francine Zhifen , MOORE, Paul A. , JOHNSON, Leslie S.
IPC分类号： A61K39/00 , C07K16/28 , C07K16/30

2. 发明公开

EP2021029A2 HUMANIZED FC RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF 失效转让
标题翻译：人源化FC-γ-RIIB，特异性抗体和申请流程。
公开(公告)号：EP2021029A2
公开(公告)日：2009-02-11
申请号：EP07873826.7
申请日：2007-05-25
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling
IPC分类号： A61K39/395 , A61P43/00 , C07H21/04 , C07K16/18 , C12N15/00 , C12N5/06 , C12P21/04 , G01N33/564
CPC分类号： A61K39/39 , A61K2039/505 , A61K2039/55516 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/52 , G01N33/564 , G01N33/6893 , G01N2800/24
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

3. 发明公开

EP3558391A1 IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF 有权
公开(公告)号：EP3558391A1
公开(公告)日：2019-10-30
申请号：EP17835533.5
申请日：2017-12-21
申请人： Immunogen, Inc. , MacroGenics, Inc.
发明人： HICKS, Stuart William , YODER, Nicholas C. , BARAT, Bhaswati , BONVINI, Ezio , DIEDRICH, Gundo , JOHNSON, Leslie S. , LOO, Deryk , SCRIBNER, Juniper A.
IPC分类号： A61K47/68 , A61P35/00 , C07K16/40 , C07K16/28 , C07K16/30

4. 发明授权

EP2714079B2 DEIMMUNIZED SERUM-BINDING DOMAINS AND THEIR USE FOR EXTENDING SERUM HALF-LIFE 无效转让
公开(公告)号：EP2714079B2
公开(公告)日：2019-08-28
申请号：EP12789439.2
申请日：2012-05-16
申请人： MacroGenics, Inc.
发明人： BONVINI, Ezio , BARAT, Bhaswati , HUANG, Ling , JOHNSON, Leslie S.
IPC分类号： A61K39/395 , C07K16/28 , C07K16/32 , C07K16/44

5. 发明授权

EP3030264B1 BI-SPECIFIC MONOVALENT FC DIABODIES THAT ARE CAPABLE OF BINDING CD32B AND CD79B AND USES THEREOF 有权转让
公开(公告)号：EP3030264B1
公开(公告)日：2019-01-09
申请号：EP14834798.2
申请日：2014-08-06
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling , SHAH, Kalpana , BONVINI, Ezio , MOORE, Paul A. , CHEN, Wei
IPC分类号： A61K39/395

6. 发明公开

EP2815764A1 Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity 审中-公开
标题翻译：根据具有减小了毒性单克隆抗体用于治疗自身免疫性疾病的方法
公开(公告)号：EP2815764A1
公开(公告)日：2014-12-24
申请号：EP14166617.2
申请日：2007-06-14
申请人： MACROGENICS, INC.
发明人： KOENIG, Scott , BONVINI, Ezio , JOHNSON, Leslie S. , WILDER, Ronald , PILLEMER, Stanley
IPC分类号： A61K39/395 , A61K39/40 , A61K39/21 , A61P37/00 , C07K16/28
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present disclosure provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes ( i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the disclosure are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the disclosure provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the disclosure provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供了治疗，预防，减缓进展，或改善T细胞的症状介导的免疫疾病，特别是自身免疫性疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖型糖尿病（IDDM））和方法多发性硬化）通过使用抗人CD3抗体。本公开的抗体在低剂量给药方案优选使用的，慢性的给药方案或方案的一定时间之后也涉及再次给药。本公开的方法提供了抗体的施用特异性结合所做的人CD3复合物内的ε亚基。搜索抗体调节T细胞受体/同种异体抗原相互作用，并且因此调节与自身免疫性疾病相关联的T细胞介导的细胞毒性。另外，本公开的方法提供了使用改性寻求thatthey表现出降低或消除效应子功能和T细胞活化相比于未修饰的抗人CD3抗体的抗人CD3抗体。

7. 发明公开

EP2252631A2 BCR-COMPLEX-SPECIFIC ANTIBODIES AND METHODS OF USING SAME 有权转让
标题翻译： BCR-复合物特异性抗体和使用方法
公开(公告)号：EP2252631A2
公开(公告)日：2010-11-24
申请号：EP09763010.7
申请日：2009-03-25
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： Chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

8. 发明公开

EP3954703A3 TRI-SPECIFIC BINDING MOLECULES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：EP3954703A3
公开(公告)日：2022-05-18
申请号：EP21185550.7
申请日：2015-05-29
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling , CHICHILI, Gurunadh Reddy , SHAH, Kalpana , LAM, Chia-Ying, Kao , BURKE, Stephen, James , LIU, Liqin , MOORE, Paul, A. , BONVINI, Ezio , BARAT, Bhaswati
IPC分类号： C07K16/18 , C07K16/28 , C07K16/30 , A61P1/04 , A61P1/16 , A61P5/00 , A61P9/10 , A61P11/00 , A61P13/10 , A61P13/12 , A61P17/00 , A61P19/00 , A61P21/00 , A61P35/02 , A61P35/00 , A61P35/04 , A61P1/18 , A61P13/00 , A61P13/08 , A61P15/00 , A61P25/00
摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.

9. 发明授权

EP3035965B1 BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD123 AND CD3, AND USES THEROF 有权转让
公开(公告)号：EP3035965B1
公开(公告)日：2020-11-11
申请号：EP14837858.1
申请日：2014-08-20
申请人： MacroGenics, Inc.
发明人： BONVINI, Ezio , JOHNSON, Leslie S. , HUANG, Ling , MOORE, Paul A. , CHICHILI, Gurunadh Reddy , ALDERSON, Ralph Froman
IPC分类号： A61P11/06 , A61P17/02 , A61P19/02 , A61P35/04 , A61P37/00 , A61P37/08 , C07K16/28 , A61K39/00 , A61P35/00 , A61P35/02 , A61P29/00

10. 发明公开

EP3035956A2 BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF 有权转让
标题翻译：双特异性双抗体MONO VALENTE与能力GPA33结合和其用途和CD3
公开(公告)号：EP3035956A2
公开(公告)日：2016-06-29
申请号：EP14837376.4
申请日：2014-08-20
申请人： MacroGenics, Inc.
发明人： MOORE, Paul A. , LI, Jonathan , CHEN, Francine Zhifen , JOHNSON, Leslie S. , SHAH, Kalpana , BONVINI, Ezio
IPC分类号： A61K39/00 , C12P21/08 , C07K16/00
摘要： The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a "gpA33 x CD3 bi-specific monovalent diabody"). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 ( i.e ., a "gpA33 x CD3 bi-specific monovalent Fc diabody"). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.
摘要翻译：本发明涉及双特异性双抗体的单价确实包含两条多肽链和其中在gpA33（即，“gpA33 X CD3双抗体的表位具有特异性的CD3处的表位特异性针对至少一个结合位点和一个结合位点具体单价双体“）。因此，本发明涉及双特异性单价双抗体做了包括免疫球蛋白Fc结构域（“双特异性单价的Fc双抗体”）的和由三个多肽链和其具有特异于至少一个结合位点在gpA33的表位和特异于CD3的表位的结合位点（即，一个“gpA33 X CD3双特异性单价的Fc双抗体”）。所述双特异性单价双抗体和本发明的双特异性单价的Fc抗体是能够同时结合gpA33和CD3的。本发明涉及药物组合物的确含有寻求双特异性单价双体或寻求双特异性单价的Fc双体。本发明另外涉及用于在癌症和其它疾病和病症的治疗中使用的搜索双抗体的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式